Patient Demographics and Baseline Disease Characteristics in MARIPOSA-2
In this segment the panelist reviews the baseline patient and disease characteristics across the three treatment arms in MARIPOSA-2.
Achieving Precision With Radiation Oncology Advancements in NSCLC
The use of CT scans may help practices adaptively plan and adjust radiotherapy courses for patients with non–small cell lung cancer.
Minimizing Toxicity in NSCLC Management With Proton Beam Radiotherapy
Patients with NSCLC who have comorbidities or frailty may also be able to receive treatment with fewer toxicities via proton beam radiotherapy.
Combining Immunotherapy With Radiation Oncology in NSCLC
Terrence T. Sio, MD, MS, emphasizes multidisciplinary collaboration for treating patients with NSCLC who may require more than 1 type of therapy.
Recent Bispecific Antibody Approvals in Relapsed/Refractory MM
The panel discusses recent updates on bispecific antibodies for patients with relapsed/refractory multiple myeloma, highlighting studies investigating talquetamab, teclistamab, and elranatamab.
Key Takeaways from the CARTITUDE-1 and KarMMa Studies
Focusing on later lines of therapy for patients with relapsed/refractory multiple myeloma, the panel provides key takeaways on the CARTITUDE-1 and KarMMa trials that investigated cilta-cel and ide-cel.
CAR T-Cell Therapy in Earlier Treatment Lines for Relapsed/Refractory Multiple Myeloma
A panel of experts on multiple myeloma introduce themselves and discuss recent CAR T-cell therapy approvals in earlier treatment lines for patients with relapsed/refractory disease.
How CAR T-Cell Therapy Impacts Relapsed/Refractory MM Treatment
Yi Lin, MD, PhD, provides insights on the impact of CAR T-cell therapy on the evolving multiple myeloma treatment landscape.
MARIPOSA-2 Phase 3 Study Design and Treatment Arms
This segment discusses the details of the phase 3 randomized MARIPOSA-2 trial design evaluating amivantamab plus chemotherapy vs amivantamab, lazertinib and chemotherapy vs chemotherapy alone in osimertinib-resistant EGFR-mutant NSCLC.
Background on Osimertinib Resistance Mechanisms and Unmet Needs Driving Evaluation of Novel Therapies
This segment introduces a discussion on the MARIPOSA-2 trial evaluating amivantamab plus chemotherapy or amivantamab, lazertinib and chemotherapy in EGFR-mutant NSCLC after osimertinib progression.
Adverse Effects Associated With JAK Inhibitors in Myelofibrosis
Naveen Pemmaraju, MD, discusses adverse effects associated with JAK inhibitors in the treatment of myelofibrosis, and the Oncology Brothers recap the entire discussion.
Managing Anemia and Splenomegaly in Myelofibrosis
An expert on myelofibrosis discusses anemia and splenomegaly management practices for patients with myelofibrosis.
JAK Inhibitors in Myelofibrosis
Naveen Pemmaraju, MD, gives a comprehensive overview of JAK inhibitors available for the treatment of patients with myelofibrosis.
Supportive Care in Myelofibrosis
A hematology specialist provides clinical insights on supportive care practices for patients with myelofibrosis.
Patient Diagnostic Workup Practices
Naveen Pemmaraju, MD, joins Rohit Gosain, MD, and Rahul Gosain, MD, to discuss diagnostic practices and prognostic factors for patients with myelofibrosis.
The Impact of CAR T-Cell Therapy on Relapsed/Refractory MM Treatment
Rahul Banerjee, MD, FACP, discusses how the emergence of CAR T-cell therapy has impacted the multiple myeloma treatment landscape by addressing unmet needs and improving patients’ quality of life.
Unmet Needs and Future Perspectives on the Treatment of EGFR-Mutated NSCLC
The expert panel concludes with thoughts on unmet needs and future perspectives on the treatment of patients with EGFR-mutated non–small cell lung cancer.
The Rationale for CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
A panel of experts on multiple myeloma discuss the rationale for CAR T-cell therapy, highlighting BCMA as a target and treatment administration practices.
NSCLC with EGFR Exon 20 Insertions: Updated Data from PAPILLON
Medical oncologists review updated data from the PAPILLON trial on amivantamab plus chemotherapy and discuss the treatment of patients with NSCLC with EGFR exon 20 insertions.
Closing Thoughts on the Future of NSCLC
In their closing remarks, the panel reflects on the presented patient cases and shares insights on the future of non-small cell lung cancer (NSCLC) treatment.
.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "A panel of 4 experts on lung cancer")
.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Video 8 - \"Closing Thoughts on the Future of NSCLC\"")
